<SEC-DOCUMENT>0001213900-21-057799.txt : 20220112
<SEC-HEADER>0001213900-21-057799.hdr.sgml : 20220112
<ACCEPTANCE-DATETIME>20211109172300
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001213900-21-057799
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20211109

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEKTAR THERAPEUTICS
		CENTRAL INDEX KEY:			0000906709
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				943134940
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		455 MISSION BAY BOULEVARD SOUTH
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		4154825300

	MAIL ADDRESS:	
		STREET 1:		455 MISSION BAY BOULEVARD SOUTH
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INHALE THERAPEUTIC SYSTEMS INC
		DATE OF NAME CHANGE:	19980723

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INHALE THERAPEUTIC SYSTEMS
		DATE OF NAME CHANGE:	19940303
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Nektar Therapeutics</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">455 Mission Bay Boulevard South</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">San Francisco, California 94158-2117</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">November 9, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>VIA EDGAR</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Office of Life Sciences</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">United States Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Division of Corporation Finance</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">100 F Street, N.E.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attention: Mary Mast, Senior Staff Accountant</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="background-color: white">
    <TD STYLE="width: 0.5in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Re:</B></FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Nektar Therapeutics</B></FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Form 10-K for the Fiscal Year Ended December 31, 2020</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Filed February 26, 2021</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Form 10-Q for the Quarterly Period Ended June 30, 2021</B></P></TD></TR>
  <TR STYLE="background-color: white">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Filed August 6, 2021</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>File No. 000-24006</B></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Ms. Mast:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are in receipt of the letter from the staff
(the &ldquo;<B>Staff</B>&rdquo;) of the Securities and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;) dated October 26, 2021,
regarding the Annual Report on Form 10-K for the fiscal year ended December 31, 2020 (File No. 000-24006) and the Quarterly Report on
Form 10-Q for the quarterly period ended June 30, 2021 (File No. 000-24006) filed by Nektar Therapeutics, a Delaware corporation (the
&ldquo;<B>Company</B>&rdquo; or &ldquo;<B>we</B>&rdquo;), on February 26, 2021 and August 6, 2021, respectively. Set forth below is the
Company&rsquo;s response to the Staff&rsquo;s comment set forth in the letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Staff Comment:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Form 10-Q for the Quarterly Period Ended June
30, 2021</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Note 4 &ndash; Co-Development Agreement with SFJ Pharmaceuticals
and Development Derivative Liability, page 16</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD><I>Please provide us with your accounting analysis supporting the classification of this co-development agreement as a derivative
liability. As part of your response, please explain how you determined the agreement met the definition of a derivative under ASC 815
as well as your consideration of any applicable scope exceptions. Please also explain how you determined that changes in the fair value
of your development derivative liability should be classified as non-operating income/expense in your Statement of Operations given that
product development is integral to your operations.</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Response:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">With regard to the Staff&rsquo;s comment about
our treatment of the SFJ co-development agreement (the &ldquo;<B>SFJ Agreement</B>&rdquo;), we respectfully advise the Staff that, as
we have previously disclosed in our public filings, SFJ and we have agreed that SFJ will fund up to $150.0 million (the &ldquo;<B>Funding
Commitment</B>&rdquo;) to conduct a Phase 2/3 study in squamous cell cancer of the head and neck (the &ldquo;SCCHN Indication&rdquo; and
the &ldquo;<B>SCCHN Clinical Trial</B>&rdquo;). We are the sponsor for the SCCHN Clinical Trial, responsible for developing the protocol,
data analysis, pharmacovigilance and regulatory activities, including filing the Biologics License Application (&ldquo;<B>BLA</B>&rdquo;),
if the SCCHN Clinical Trial is successful. SFJ will act as our contract research organization (&ldquo;<B>CRO</B>&rdquo;) but will primarily
outsource such responsibilities to PPD, which has been our CRO for our bempegaldesleukin program, as well as other third-party vendors.
SFJ&rsquo;s Funding Commitment also includes quarterly payments to us since we are providing resources to conduct the SCCHN Clinical Trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As we have previously disclosed in our public filings, in exchange
for the Funding Commitment, we will pay SFJ a series of success-based annual payments (collectively, the &ldquo;<B>Success Payments</B>&rdquo;)
of up to $637.5 million in the event of FDA approval of bempegaldesleukin for first-line metastatic melanoma<SUP>1</SUP> (the &ldquo;<B>Melanoma Indication</B>&rdquo;), the SCCHN Indication,
or both, and in the
event of FDA approval of one additional bempegaldesleukin indication. The SCCHN Clinical Trial also provides for an interim futility analysis.
If the success criterion for the interim futility analysis is not met and SFJ winds down the SCCHN Clinical Trial, then the Success Payments,
if any, for the Melanoma Indication and/or the additional bempegaldesleukin indication are reduced pro rata based on the costs incurred
by SFJ for the SCCHN Clinical Trial over the aggregate commitment of $150.0&nbsp;million. In the event that bempegaldesleukin is not approved
in one or more indications, SFJ will bear the full cost of conducting the clinical trial and has no right to be reimbursed by Nektar.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Success Payments for the Melanoma Indication
and an additional bempegaldesleukin indication are based on registrational trials for bempegaldesleukin in combination with nivolumab
under our Strategic Collaboration Agreement with Bristol Myers-Squibb Company (&ldquo;<B>BMS</B>&rdquo;). SFJ has no decision-making rights
or any involvement in the conduct of this collaboration, the clinical trials or the filing of a BLA for these indications. Because SFJ
has a right to consideration based on the results of these studies, we concluded that the SFJ Agreement is outside the scope of a collaborative
or research and development arrangement and determined that it is a financing arrangement. SFJ is investing in the overall bempegaldesleukin
program through its funding of a trial for which we have no prior efficacy data, and, in return for this risk, has the opportunity to
earn a return on investment based on the overall success of bempegaldesleukin, as measured by potential future FDA approvals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">1</TD><TD STYLE="text-align: justify">The registrational study for first-line metastatic melanoma
is being conducted by Bristol Myers-Squibb Company pursuant to our Strategic Collaboration Agreement, as disclosed in Note 8 to our Form
10-Q for the Quarterly Period Ended June 30, 2021.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In our assessment of whether these terms met the
definition of a derivative, we considered the definition of a derivative provided by ASC 815-10-15-83, and the related guidance on an
underlying, notional amount, payment provision and initial net investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">815-10-15-83: <I>A derivative instrument
is a financial instrument or other contract with all of the following characteristics:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><I>a. Underlying, notional amount, payment
provision. The contract has both of the following terms, which determine the amount of the settlement or settlements, and, in some cases,
whether or not a settlement is required:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><I>1.One or more underlyings.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><I>2. One or more notional amounts or
payment provisions or both.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><I>b. Initial net investment. The contract
requires no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that
would be expected to have a similar response to changes in market factors.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><I>c. Net settlement. The contract can
be settled net by any of the following means:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><I>1. Its terms implicitly or explicitly
require or permit net settlement.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><I>2. It can readily be settled net
by a means outside the contract.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><I>3. It provides for delivery of an
asset that puts the recipient in a position not substantially different from net settlement.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B><I>Underlying</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">815-10-15-88: <I>An underlying is a
variable that, along with either a notional amount or a payment provision, determines the settlement of a derivative instrument. An underlying
usually is one or a combination of the following:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><I>a. A security price or security price
index</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><I>b. A commodity price or commodity price
index&#9;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><I>c. An interest rate or interest rate
index</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><I>d. A credit rating or credit index&#9;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><I>e. An exchange rate or exchange rate
index</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><I>f. An insurance index or catastrophe
loss index</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><I>g. A climatic or geological condition
(such as temperature, earthquake severity, or rainfall), another physical variable, or a related index</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><I>h. The occurrence or nonoccurrence
of a specified event (such as a scheduled payment under a contract).</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">15-89: <I>However, an underlying may
be any variable whose changes are observable or otherwise objectively verifiable. An underlying may be a price or rate of an asset or
liability but is not the asset or liability itself.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">15-90: <I>Reference to either a notional
amount or a payment provision is needed in relation to an underlying to compute the contract's periodic settlements and resulting changes
in fair value.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B><I>Notional Amount</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">815-10-15-92: <I>A notional amount is
a number of currency units, shares, bushels, pounds, or other units specified in the contract. Other names are used, for example, the
notional amount is called a face amount in some contracts. The settlement of a derivative instrument with a notional amount is determined
by interaction of that notional amount with the underlying. The interaction may be simple multiplication, or it may involve a formula
with leverage factors or other constants. As defined in the glossary, the effective notional amount is the stated notional amount adjusted
for any leverage factor. If a requirements contract contains explicit provisions that support the calculation of a determinable amount
reflecting the buyer&rsquo;s needs, then that contract has a notional amount. See paragraphs 815-10-55-5 through 55-7 for related implementation
guidance. For implementation guidance on identifying a commodity contract's notional amount, see paragraph 815-10-55-5.</I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I></I></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B><I>Payment Provision</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">815-10-15-93: <I>As defined in the glossary,
a payment provision specifies a fixed or determinable settlement to be made if the underlying behaves in a specified manner. For example,
a derivative instrument might require a specified payment if a referenced interest rate increases by 300 basis points.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B><I>Initial Net Investment</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">815-10-15-94: <I>Many derivative instruments
require no initial net investment. Some require an initial net investment as compensation for one or both of the following:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><I>a. Time value (for example, a premium
on an option)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><I>b. Terms that are more or less favorable
than market conditions (for example, a premium on a forward purchase contract with a price less than the current forward price).</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>Others require a mutual exchange
of currencies or other assets at inception, in which case the net investment is the difference in the fair values of the assets exchanged.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">15-95: &#9;<I>A derivative instrument
does not require an initial net investment in the contract that is equal to the notional amount (or the notional amount plus a premium
or minus a discount) or that is determined by applying the notional amount to the underlying. For example:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><I>a. A commodity futures contract generally
requires no net investment, while purchasing the same commodity requires an initial net investment equal to its market price. However,
both contracts reflect changes in the price of the commodity in the same way (that is, similar gains or losses will be incurred).</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><I>b. A swap or forward contract generally
does not require an initial net investment unless the terms favor one party over the other.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><I>c. An option generally requires that
one party make an initial net investment (a premium) because that party has the rights under the contract and the other party has the
obligations.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>15-96: &#9;If the initial net investment
in the contract (after adjustment for the time value of money) is less, by more than a nominal amount, than the initial net investment
that would be commensurate with the amount that would be exchanged either to acquire the asset related to the underlying or to incur the
obligation related to the underlying, the characteristic in paragraph 815-10-15-83(b) is met. The amount of that asset acquired or liability
incurred should be comparable to the effective notional amount of the contract. This does not imply that a slightly off-market contract
cannot be a derivative instrument in its entirety. That determination is a matter of facts and circumstances and shall be evaluated on
a case-by-case basis. Example 16, Case C (see paragraph 815-10-55-166) illustrates the guidance in this paragraph.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We concluded that the SFJ Agreement contains the
following four key elements of a derivative as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><B>Underlying:</B> The underlyings are the FDA approvals of bempeg in the Melanoma Indication, the SCCHN Indication and another bempegaldesleukin
indication, as these approvals trigger the Success Payments, which represent SFJ&rsquo;s opportunity to earn a return on its investment
(payment provision). While the FDA approvals of bempegaldesleukin in the Melanoma Indication and another bempegaldesleukin indication
are not related to the conduct of the SCCHN Clinical Trial, there is no requirement that an underlying be related to the consideration
provided by SFJ. This type of underlying is consistent with ASC 815-10-15-88(h) for the &ldquo;occurrence or nonoccurrence of a specified
event,&rdquo; in this case, the FDA approval or non-approval of one or more bempegaldesleukin BLAs.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><B>Notional amount or payment provision:</B> The SFJ Agreement contains a payment provision because it specifies fixed payment amounts
of up to $637.5 million and the timing of the payments over up to a seven-year period based on the occurrence of the FDA approvals.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                                                                             </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><B>No initial or nominal net investment:</B> SFJ is not required to and did not make a payment to us at inception, so this requirement
has been met. However, we note that SFJ has agreed to the Funding Commitment, which is the consideration in the contract. Accordingly,
in theory, if SFJ were to pay us the fair value of the Funding Commitment at inception, we would be in the same economic position. As
such, we considered whether this amount of consideration/investment would continue to meet the requirement of ASC 815-10-15-83(b), and
note that, since SFJ has the rights to receive the Success Payments and we have the obligation to pay the Success Payments, the arrangement
is similar to an option as described in ASC 815-10-15-95(c). Given the magnitude of the Success Payments of $637.5 million as compared
to the estimated $114.5 million fair value of Funding Commitment, we concluded that this investment is significantly less than the amount
&ldquo;to incur the obligation related to the underlying&rdquo; after considering the time value of money, as described in ASC 815-10-15-96.
Accordingly, whether one considers the initial net investment to be $0 or the fair value of the Funding Commitment, the requirement in
ASC 815-10-15-83(b) is met.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><B>Net settlement provision:</B> We are required to pay the Success Payments to SFJ, as the Success Payments represent the payment
provision based on the underlying of the FDA approval of bempegaldesleukin. Since the payment is unidirectional, it can only represent
a net settlement provision. We concluded that we should not consider the Funding Commitment in our analysis of the net settlement provision,
since it represents the consideration/nominal net investment in the contract.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">With respect to the scope exceptions for ASC 815-10,
as provided in ASC 815-10-15-13, we believe that it is evident that none of the scope exceptions would apply to the SFJ Agreement, other
than ASC 815-10-15-13(e) for &ldquo;Certain contracts that are not traded on an exchange.&rdquo; Accordingly, we analyzed the guidance
in ASC 815-10-15-59 for the application of this scope exception, which states &ldquo;Contracts that are not exchange-traded are not subject
to the requirements of this Subtopic if the underlying on which the settlement is based is any one of the following:&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>&nbsp;</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; border: black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt"><I>a. A climatic or geological variable or other physical variable. Climatic, geological, and other physical variables include things like the number of inches of rainfall or snow in a particular area and the severity of an earthquake as measured by the Richter scale. (See Example 13 [paragraph 815-10-55-135].)<BR>
<BR>
</I></FONT></TD>
    <TD STYLE="width: 50%; border-top: black 1.5pt solid; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>No,</B> the FDA approval of bempegaldesleukin is the underlying, which is not a climatic, geological or other physical variable.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>b. The price or value of a nonfinancial asset of one of the parties
    to the contract provided that the asset is not readily convertible to cash. This scope exception applies only if both of the following
    are true:</I></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>1. The nonfinancial assets are unique. </I></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>2. The nonfinancial asset related to the underlying is
    owned by the party that would not benefit under the contract from an increase in the fair value of the nonfinancial asset. (If the contract
    is a call option, the scope exception applies only if that nonfinancial asset is owned by the party that would not benefit under the contract
    from an increase in the fair value of the nonfinancial asset above the option&rsquo;s strike price.)</I></P></TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>No,</B> the nature of the underlying in this agreement is an event
    (ie. a regulatory decision in the form of the occurrence or nonoccurrence of FDA approval), rather than a price or value change of the
    nonfinancial asset.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Although the FDA approval of bempegaldesleukin would certainly increase
    the value of the clinical program and the drug compound, the underlying of the approval, in and of itself, is not based on the &ldquo;price
    or value&rdquo; of bempegaldesleukin, but rather on the FDA&rsquo;s conclusions regarding bempegaldesleukin&rsquo;s therapeutic benefit.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Finally, we believe that an affirmative response to this criterion,
    requires yes responses to b, b1 and b2. Even if the responses to b1 and b2 are &ldquo;yes,&rdquo; given the response above in b, we do
    not believe this transaction meets this scope exception.<BR>
    <BR>
    </P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt"><I>c. The fair value of a nonfinancial liability of one of the parties to the contract provided that the liability does not require delivery of an asset that is readily convertible to cash.<BR>
<BR>
<BR>
</I></FONT></TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>No</B>, the FDA approval of bempegaldesleukin is the underlying, which is not related to a nonfinancial liability.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt"><I>d. Specified volumes of sales or service revenues of one of the parties to the contract. (This scope exception applies to contracts with settlements based on the volume of items sold or services rendered, for example, royalty agreements. This scope exception does not apply to contracts based on changes in sales or revenues due to changes in market prices.)</I></FONT></TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>No</B>, the FDA approval of bempegaldesleukin is the underlying, which is not based on the volume of sales of bempegaldesleukin.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">With respect to the Staff&rsquo;s question about
the income statement presentation for the change in the fair value of the development derivative liability, we respectfully advise the
Staff that we present the costs incurred by SFJ as it conducts the SCCHN Clinical Trial within Research and development expense within
our Statement of Operations, since we concur with the Staff that clinical trial costs are part of our &ldquo;major ongoing or central
operations&rdquo; as provided by Financial Accounting Concepts 6.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Over the life of the SFJ Agreement, the cumulative
amount recognized for the remaining change in the fair value of the derivative liability will equal the difference between the costs incurred
by SFJ to conduct the SCCHN Clinical Trial and the aggregate amount of Success Payments, if any, that we pay to SFJ upon approval. This
change in the fair value of the development derivative liability, which we present within nonoperating income/expense, is determined by
our quarterly updates to our assumptions regarding the probability success for the FDA approval of bempegaldesleukin, the probability
of success for the interim futility analysis for the SCCHN Clinical Trial, and the discount rates used in estimating the fair value of
the liability. We accrete this change in the fair value of the derivative liability based on the discounted cashflows over the passage
of time associated with the development period and the related funding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We concluded that this change in fair value reflects
a gain or loss on the financing of the SCCHN Clinical Trial in that SFJ is acting as an investor in our bempegaldesleukin program through
its Funding Commitment and bears the risks and rewards of its investment based on the success of bempegaldesleukin as measured by the
FDA approval of bempegaldesleukin, including approvals based on studies conducted under our Strategic Collaboration Agreement with BMS
and in which SFJ has no involvement. Accordingly, we concluded that it is appropriate to present this component of the change in fair
value of the development derivative liability within non-operating income/expense. We have consistently presented the income statement
effects of financing transactions as non-operating income/expense, including our non-cash interest expense on the sales of future royalties<SUP>2</SUP>,
our interest expense on our Senior Secured Notes<SUP>3</SUP> and interest income on our investments in marketable securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">* * * * *</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company hereby acknowledges that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the Company is responsible for the adequacy and accuracy of the disclosure in the filings;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with
respect to the filing; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the Company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal
securities laws of the United States.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">2</TD><TD STYLE="text-align: justify">Please see Note 7 to our Form 10-K for the period ended December
31, 2020 for additional information.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">3</TD><TD STYLE="text-align: justify">Please see Note 5 to our Form 10-K for the period ended December
31, 2020 for additional information.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If you have additional questions, please do not
hesitate to contact the undersigned at (415) 482-5570 or Jillian B. Thomsen, Senior Vice President, Finance and Chief Accounting Officer,
at (415) 482-5555.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%; text-align: justify"><FONT STYLE="font-size: 10pt">Sincerely,</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">/s/ Gil M. Labrucherie</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Gil M. Labrucherie</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Senior Vice President and Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">cc:</FONT></TD>
    <TD STYLE="width: 95%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Jillian B. Thomsen, Senior Vice President, Finance and Chief Accounting Officer of Nektar Therapeutics</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Mark A. Wilson, Senior Vice President and General Counsel of Nektar Therapeutics</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Mitchell Bloom, Esq., Goodwin Proctor LLP</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">8</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  > )4# 2(  A$! Q$!_\0
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M(GE3#"2V34;*W%W%M)DMFE4$-M(^AOV1OC+KW[+WQSU7P+X_\[1/#7B#6/\
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MPU2AB:L%#/*L^>%/$MPY*51J?*U%\I^2?CN\O#^U!XIB%[>B+_AH"]41K=W
MC"'XA@;1'Y@39CJFW:1D$=J_?S]I3]HSPE^SKX)F\0ZT(=5\2ZF;FT\'>$HY
MA'>Z_J4:\R2,-SVFC:>9$FU;42I2&(K;P[[R>&(_SS?%74O[&_:&^(>M&$W'
M]C_&;Q%J_P!GW^69_P"S/&5Q??9_,VL4\W[/Y7F;'V%MVQL!3D_%WXN>+_C9
MX^U;Q]XXO6NK^^D\BRTZU<_8?#VAQS.]IH6B03,4BM[6-V(EF)EOKQI+R\=I
M)6V_D_ _T@*O@WE_CE@<HC4Q7&O%?'E?#</5L0I2R[)\/A\?Q1A\=G6)G4E4
MHRG@ZF+H0P6"C&I&>*E&O6YL'A9T<7]OQ'X6KQ"Q/AIB<?*-'AS(^$Z%;-HT
M91CB\PJ5</DE;#Y?AXQC&K3CB88>4JV*^*%&U.BYXBI"=+TC0?#/[0_[8/Q#
M\5Z_HL.H^*_$KHNI:[?2:J- \-:':.?+TW1[6XN[B*PT^".(&'2=)A+7#012
MW#K(?M%PVY\0OV/?VE?A=X.UKQYXRT:TL/"_AV"&YU>\M/'FGZE<00W%W;V4
M+165I>-<3DW5U I2-6(5F<X"9K]R?V5M&^$^E?!'P/+\'(XF\(ZIIRZD;Z4(
M=;U'6Y$2'6[CQ/(@!/B"&^CFL]0A($=HT2VUJJ6D4(/-?MS?\FI_&'_L"Z3_
M .I/H=?OE?Z(_"LO"?.O$;BSC+B;B;CFMPCG7&^*S;*<^@LAQN95LIQ>?894
MU/"8FKC\,IRI0KXM8FBL<W7G1IX2A]7IT?S2AX[Y[_KMEG">0Y#D^2<,T\]R
MSARAE^,RIK,\-@X8^AEE;VG+B*%+"XB455G"@J%58>4DIU,34=:<_P "?A%\
M)?BI\=-?U'PS\-87U;5])TK^V[^&^\2IH\,6G"[ALO.6XO[F.*247-Q!'Y*$
MN5<R<*&K]$/V6/V8?CI\!?B];?%/XMZ;I^D^ O#?@_QM+KFHQ^,]-UAK9&T5
MY(W^PP74DS +#(6F5"L0&2P!R>!_X):<?&KX@>_PS;/X^)M&'^?ZU]L_\%&/
MBF/ OP$N_"EC<>5KOQ0U2/PE%&K$3+X?@5-1\37"A#N5'M([?2W;'_,3 ]C\
M/X$>&' &3^#6'^D?Q!F/$BXBX)QG$.<X7"T\XA2R3%X_A[%2PV1X6O@*N#JU
M*BQN-QN&H5XK&1=5U%R.'LVI?1>)W&G%>8^(6)\(<KH90LHXCHY1EU:O/+I3
MS&AALUP]/$YE7ABHXJ"C]6P]#$5H2]@_9JE%67/=?AK\3/B-KOQ.\?\ C/Q]
MJ%Y?I)XLU_4-62W6YN5BL]/FF$>EV(C23RXTL]-CL[-1M4%HN 2<'][?V!/B
MF_Q+_9]\/V=_=FY\0?#J:3P'K#2R&2XDMM-5)_#MW*[$NWGZ%<6D&]B2TMG-
MDLRG'YU?LK?LU-\4/V;OVB/%<]@)M7\0:>OA_P"'LTD:EEU#P2T?BF[N;1B&
M8'4-8CL-&,B[0T=O<1$G<RBK_P $U_BB_A#XTWW@*^N3;:5\4=%:S@BD;RXT
M\6>'EGU'205;&)[NP;5[  89Y?L\>,A0?+^CWF/%WACXL>''%O&.+K/*?I%Y
M9GKK2Q$JT52Q^,XAQD\KJXE5Y\JJU,SAAL31G"R6!SG#PIITZD.?M\5<)D?&
M/!/%V09#AZ<<?X18[*U"%/V4ISPE'*,+3Q\:*IP<U3AA'4HU(MR_VG+:TY-2
M@^3TK_@JG<W-O\0O@]Y%S<0!_!?BG<(9Y8=Q77M.P3Y;J20">3G X&,G/S/\
M)_V-_C]\:/!&F_$+P5?>'#X>U6XU&VM3K/C'4=.OS+I=[-878EM$T^Z1%%Q!
M)Y;"=]\>UB%R /I+_@JQ_P E!^#F>O\ PAGBKOG@:[IP'<]L5UO[(W[:'P+^
M#?P+\,^ /&^J>)+;Q'I6H^([F[@T[PQJ&IVBQZIKE[?VICO+<^5(6MYHV=1A
MD<E",KSZ'%_#OAIQ7]+GQ8RSQ9XBEP]PQ0R_#XO!XN7$+X>I2S>&4\+4L-AX
MXR5+$0G*I1JXF<:"IJ<W3]I"<'33.7(LXXSR3P(X%QG N5O-,YJXRM0KT(90
MLUJ1P$L?GTZM1X=.G**C6A03JN;Y'*,=VK_$OQ:_9U_:&_9ICT;Q=XGN;C3+
M*XOXK2P\5>"_&-_=)I^K%)+BUM;JYMCIVH:=<3I!*]G(\7V:X:)XTG,H$3?H
M-^S'X\\4?M?_  ?UKP#XXUU9_&7PUUW2Y;K6[ZT\V+Q7X=U:SODTBYUN&W$:
MR:OIEW:W,4EVL3BYD@MKJ2 7-S+<1>-?MJ_MH?#+XU_#BU^&WPUM/$%^;SQ!
MH^M:SK.M:0='M;*WT9KB:WLK&WN)9+RZO;JZEB$D@AA@@MXW"O-+*%7Z3_X)
ML?!7Q;\./!/C3QQXSTR\T&]^(MSH?]@Z)J,+VVI1>'-&AO9(-5OK24+-:-JU
MWJ,[VD%PJ3_8K:&X>-5N4KZ+PGX>R#+?I)8G@CP@XDSCC#P?S#A*K5XXYLTQ
M>;9+AZ];!UZL82S*G1PV$J8JEF>&RR&#Q4*%+$RGB,7@XU<32IUH1\CCC,\S
MQ_A%1XBX_P HP&0\?8;/J<.&YK 8?+\SQ%&EBJ<93>#E*M7CAYX2KC)XJDZD
M\.E1PU=TL/.K#F_1KPAHTGA[POH.A2W<U_)H^EV6G/?3@B6Z:UMXXFF*M),Z
M*S*1'&\TKQQA$>61E+L5T,8PB_0'\^?ZT5_IMAZ-/#4*&'I1Y*6'HT:%*-V^
M6G1I4Z-.-Y.4GRTZ4(WE*3=KMMW;_CZ<Y5)SJ3=YU)SG-NVLISE.3T26LIR=
MDDE>R6A_,[^PMS^U?\) /^?WQ%VS_P RCK_8U]I?\%*OV>FN(;?]H+PQIQ9K
M>.TT+XE6\$9(FLCMM=#\5S(HVG[(6CT7592"?LTFFS2-LMI2?BW]A;_DZ_X2
M?]?OB']/"6OFOZ/?$&AZ5XFT75?#^NV,&IZ+K6GW>E:KI]RH>"\T^_@>UN[>
M53U$D,C 'JK;74AE4C_-'Z,/AKE?BS]&?C_@S,N2E5QO&>88C)L?*GSSRG/<
M+D>5U<KS"DU[ZC#$I4<7&$HNM@<3BJ%VI12_K_QGXNQW WC)POQ!@I3E'#\-
MX*CC\+&2C#'9;7S''4\;@ZBE>+YZ5ZM&4DU3Q-##S:Y5)GP-_P $^OVBY/BG
M\/U^&WB>]$WCSX;0V-JMQ<R9N?$'@L,EKHVIJY9FN+S2"D>C:JQR^!I]U(2U
MVS#\=+NSM-2_:5O=.O[>*\T_4?C]>V%]:7""2"[L[WXDSV]W;31G(DAN())8
MI$((:-F!'-=SJDFN_L:?M2:@OA;4VU3_ (5SXD0P[GDC&N^#-:M;>^ET+5 R
MC_2+C0[Q+*YE7S(TU&"*_@?=%&1X-XVU=-6\=>,?$%B+BTCU?QAXDUVS#.(K
MRU74==OM0MP98'/EW-N)D!DAD^65-T;\*:_ /%3Q6S'/> O#;@_C.E+%<9^#
M?B'FV0<00G4C66<9;D^%RZC@ZLL1.-?#UJTH9-7RC&.HZBK>SPF+:G"M7@_T
M[@C@C"Y=Q/Q?G_#E14.'/$/A#!YID]2,'2EEV.S&KB*N)I1HQE"<*=*69X?,
M,.H*FJ?M:M"$HRI0M_3 W[*G[. 8X^"/PZX8XQX:LAW/HG3VZ>U='X2^ WP;
M\!:Y;^)?!7PS\'^%M>MX;BTBUC1M%MK&_BM;T+'>0)<1*'6*XC4+*HX8*/2O
MY<O^$Q\8_P#0X^+O_"GUW]?^)AR?<\UZ;\%/%7BNX^,OPD@N/%?BBX@F^)?@
M:*6&?Q'K4T4L4GB734DBDCEOG1XY$)21'4HZ$HX920?WS(/IF^&>(S[),-@/
M 3+<MQN+SC*\'A<PPT^$*-?!8C&X_"8.GBJ53#<+8?$0G0EC/:J5"O1JV@U"
M<'(_,LW^CWQA0RK,\1B?$[%8S#8;+L;B:^$K1XAJ4L32PN$Q&)G0G"MGM6E*
M-6.&=.U2G."<HRE"2C8H?%S3I]7_ &@/B3HUO)'%<ZQ\8?$ND6\LV\113ZIX
MPN;"*67RT=_+CDN%>38C-L5MJLV%/Z8?M"_L-^#-/^!)'P?L$N_'GP:FNWUZ
MYAO+?4-;\?VLVEZ9K/B*+7(;89L_$%O%=0:OH&D,H>WTQ8K:V!M]6ML?G3X^
MX_:F\5X_Z.$O1^'_  L4#^7%?U%&*,L[;%W%V)..&8' 9AT8@ <L#C Q]T8X
M_HR>%G!OB<OI(9;Q+E.&Q.*Q7$N+R/!9O.E&IF&34<=F'$V.5?+*E1-8:K0S
M#"X+%\U)0E6^KRP]2?U6K.B]?&'C7B#@]^$.+R7,,1AZ&&R3#YG7P,:DHX3'
MU<-@LCPGL\93@X^VISPE;%8:,:KG"DJRK1I^VI4Y+^??]@G]ID?!_P <+X \
M57^SX;?$'4+=$N;B7%MX5\6W"QVECK.68)!INKCR--UHC:L4HL=1< 6]R6_5
MC]N1MW[*/Q@;CG1-(/RG(/\ Q4^A\@@X()R1@D8[GO\ D+^WE\"M(^#?Q?6^
M\-M:P^&OB597WBNUT.%'C&A:C]M^SZY90+L$7]FW%Y,M]IZ1L&MA//:^6D4$
M#/[QX9^/.N?%S]@7XZ^$/%7VF]\0?"G1O".C+K\SI)_;6@:AXBTUM#:[8OY[
M:MIT-C-I]W,ZE+J"&SNS(US+<J-/#'Q!SK@?(/&GZ,?'-:6)S/A;A#Q ?"&8
MPG.O2J8+"</YEC<3ECGS5)4\+5P6*P^<95[2<5AUB,PRR<8NG1;7&/"^7<29
MKX=>,O"]-4<!G?$'"L>(<)*,:4Z>+JYQ@L)3QR34/:58XRA5RW'.G%^VE1PN
M-5XU927.?\$ME ^-OQ D,C@'X7LA0M^Y^3Q1I#^9LV\2D$H7W<HJJ%X)/GG_
M  4)^)Y^(G[0=_X9TR8W6B_#&QA\(6<<.76;Q%>2)?\ B21$4'S)Q?2VNDJ4
M#.QTWRU!)Q6C_P $_O%9\">*/COXW%NUTWA#X#^(?$26JE0UQ+I.IZ=>Q19<
MA0))8HU8L0-I;@X /D_[)7AC_A;_ .U'X#7Q1<"\:Z\1:I\0_$#W :3^U+S1
M4N/$\D#*0=WVO5?(9MY55B$@SG /Y-@L[Q^>_1Y\$_!/*,1.AC_$OQ)SYXVK
M91A3RK+N)\#@L,IN\(U(_P!K8RIBITY2DZD<LI4Y)*I&I'[C$X##99XL^)7B
M-CZ:JX/@KA#*_84]+SQ^-R.O5G9I3G!_5,-"@IQC9?6JFRYD^Q^'/[0_[7OP
MH\'Z1X#\#^&M6TSPUH*7*V%K<?!Z\OKD/>7<U]=SW5Y<:49[JXN+NXEDEFE.
M\Y"9VHN/F)-<\8^!_B!IWC:XTN^\-^+M,\2VOCBUL[K2KK0'6\35CJH-KIMQ
M%;O;:==SI/:QI'']G%NTMO$2J$#^L[!YPS@YS_K)./I\W3V'X5^._P#P5.\"
M6B'X5_$V)D34+B;5_ VI*=YENK6.!_$.DS%BOS?8G&J0$.XPMVFP%0P7]:\=
M_HW<4\!^&5/C"'B]Q7QA3\+YY/F&29)G&!R["X/)<#A\9EN!J8G*JN%K>VPM
M3"0HY6Z="E%PJPPZC.3E",G\-X:^+N1\1\8O()\ 9#D4N,H8_"9GF> Q.+K8
MG'XFKA\=B84L;"M3C"M'%5*F.52M+WH.JU;DJ22\I_X*0>+=,\>ZA^SKXVT:
M1)=+\5?"_5M>LF0@A8M3U+2[ORFP3B2!Y6@E4\I+&ZL RD#UO]D3]C+X$_&/
MX$^%_'_CC1_$-WXCU74/$=O>36'BC5-,M6BTS7+VPM1'9VSB&-A;P1AV50SM
MEB>>/R]\4>.K[Q1X&^&'A2_,DG_"MK;QCI.FW#[3OTC7]9L==M;4$'?_ ,2^
MYEOH8PPVK;R0(C$1X'[V?\$\L?\ #*O@;'3^U_&?_J4ZG7C^!M3A7QP^DSQ=
MGO$_#^4\08#.?#[+\VJY;G6 IXW"X;.Z&4\&X#'U:=&O:,:E#'TLPA1JQ=_8
M5U&+E&[.[Q(IYYX;^#G#V5Y1FF.RK%9=Q=C<NCBLOQ4L/7JY?/,.(<3A83J4
MK\T:N'J82I.#NO:4FY*ZB? O[;7[&O@+X'>#=(^(_P ,)]=@TK^W[/P]XCT/
M6]3;6(H#JL-RVEZGIE[<1I>Q%;JU^R75M-+<(XN(IX7A:)Q)]7_\$T/BEXD\
M=?"WQ=X1\3:G=ZU/\.->T^QT;4=0G>ZOE\/:Y8RW5IIDUS,SSSQ:9>6=]#:&
M9W>&UDBM@QCAC"^J_P#!0#0QK'[+'Q#FWHAT.X\+:\@?)#-I_B33D=$PIP[P
M7,JJ20NXC)49-?#_ /P2M\2FU\9?%WP@8Y"VL>&_#GB2.X788T;0]2O=-EBD
M#'<&E76XFC*(P;RI Y0K'N_3HY%D_A/]-/@_*>$L+3X9X:X\X-K1QF299STL
MJQ6.6 SG; QJU*5%+%97A\7"T>2EB54J4'1]M5C/XZ6:8_CGZ/>?8W/<34SK
M.N%>):*P^98[EJ8ZAA)XC+N:+Q,H1G/_ &?'5:346G4I*,:RJNG2E#]OD^XO
=^ZO\A121_<7Z"BO]!ULO3[_/Y[_,_EQ.Z3[G_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
